Can low butyrate and short-chain fatty acid production weaken gut barrier support and increase mucosal inflammation?

Short-chain fatty acids (SCFAs), particularly butyrate, are critical signaling molecules and energy sources essential for maintaining gut homeostasis. Deficiencies in these microbial metabolites disrupt both the physical integrity and immune regulation of the intestinal tract.

Epithelial barrier degradation and antigen translocation

• Tight junction disruption: Butyrate deficiency impairs the physical barrier of the gut. Without adequate SCFA-mediated AMP-activated protein kinase (AMPK) activation and G-protein coupled receptor (GPCR) signaling, the expression and assembly of critical tight junction proteins—specifically ZO-1, occludin, and claudin-1—are significantly reduced and mislocalized.
• Luminal translocation: This structural failure increases paracellular permeability. As a result, luminal antigens, bacteria, and lipopolysaccharides (LPS) readily translocate across the compromised epithelial barrier into the lamina propria.

Loss of immune tolerance and inflammatory amplification

• Impaired tolerogenic signaling: Butyrate is a primary epigenetic and receptor-mediated driver of immune tolerance. Low levels of butyrate diminish class I/II histone deacetylase (HDAC) inhibition and reduce GPR43 and GPR109A signaling. This directly impairs regulatory T-cell (Treg) differentiation and lowers Foxp3 expression, weakening tolerogenic dendritic cell signaling.
• Pro-inflammatory cascade: The loss of butyrate-mediated suppression of NF-κB and the NLRP3 inflammasome, paired with the influx of translocated luminal antigens, drives chronic mucosal inflammation. This dual insult triggers elevated production of key inflammatory cytokines, including TNF-α, IL-6, and IL-1β.

Bottom line

• A deficiency in butyrate and other SCFAs compromises intestinal homeostasis through a feed-forward cascade: it structurally weakens the epithelial barrier (via ZO-1, occludin, and claudin-1 depletion) to allow microbial translocation, while simultaneously disabling the epigenetic (HDAC inhibition) and receptor-mediated (GPR43/GPR109A) signaling pathways required to maintain immune tolerance and suppress mucosal inflammation.